ArticleInternational journal of nanomedicine2026
Amphiphilic Chitosan-PEI Hybrid Nanocarrier Enhances Delivery Efficiency and Immunogenicity of PEDV mRNA Vaccines.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: mRNA vaccines require efficient and safe delivery systems to achieve robust antigen expression and immune activation. Chitosan is widely recognized for its biocompatibility and adjuvant properties; however, its application in mRNA delivery remains underexplored. This study aimed to develop a chitosan-derived nanoparticle system capable of enhancing mRNA transfection efficiency and vaccine immunogenicity. Methods: A novel chitosan derivative, PAN2H, was synthesized by grafting palmitic acid (PA) onto N-2-hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC). mRNA-loaded nanoparticles (PEI/mRNA/PAN2H) were constructed by first complexing mRNA with polyethyleneimine (PEI) and subsequently electrostatically binding the complex to PAN2H. Transfection efficiency was evaluated using GFP- and Luc-mRNA. Porcine epidemic diarrhea virus (PEDV) S1- and RBD-mRNA were selected as vaccine antigens for in vivo immunization to assess cellular and humoral immune responses. Results: Compared with PEI-mediated transfection, PEI/mRNA/PAN2H nanoparticles achieved approximately twofold higher expression of GFP- and Luc-mRNA in vitro, indicating that PAN2H incorporation markedly enhances mRNA transfection. In vivo, PEI/mRNA/PAN2H vaccination elicited significantly stronger antibody responses and cellular immune activation than the PEI control, supporting improved antigen expression and immune stimulation. Importantly, the PAN2H-PEI hybrid strategy provides a practical way to enhance PEI-based delivery by combining electrostatic condensation (PEI) with amphiphilicity-driven assembly and chitosan-associated biocompatibility/adjuvanticity (PAN2H). Conclusion: The cationic PEI/mRNA/PAN2H nanoparticles exhibit low cytotoxicity and markedly improved mRNA delivery capabilities. These findings highlight PAN2H as a promising chitosan-derived platform for developing next-generation mRNA vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.